Navigation Links
Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
Date:9/12/2007

SOMERSET, N.J., Sept. 12 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced it has confirmed that 290 evaluable events (patient deaths) have occurred in the Phase IIIb clinical trial of its lead compound, ONCONASE, for the treatment of patients with unresectable malignant mesothelioma. The number of evaluable events was confirmed after the company learned that total events in the study had reached 316. In accordance with the statistical plan for the study, the company must wait until 316 evaluable events have occurred to conduct the formal statistical analysis required to complete the ONCONASE New Drug Application (NDA). Enrollment in the ONCONASE Phase IIIb clinical trial is scheduled to close on Sept. 30, 2007. To date, a total of 425 patients have been enrolled in the trial.

To be considered evaluable, patients must meet all of the eligibility requirements for the study and receive at least one dose of study drug. Alfacell projects that 316 evaluable events will occur before the end of 2007. Upon reaching this milestone, the company expects to proceed using the following schedule to provide updates regarding the potential completion of the final sections of its ONCONASE rolling NDA submission:

-- Report occurrence of 316 evaluable events via news release within 72

hours of confirmation by Alfacell

-- If data are positive, submit final clinical section of rolling NDA

within four months of reporting 316 evaluable events and announce

submission via news release

Alfacell estimates that it has sufficient cash resources available to continue to fund the completion of the ONCONASE Phase III program and the rolling NDA submission.

In additi
'/>"/>

SOURCE Alfacell Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
3. Preclinical Data Show Alfacells Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
4. Researchers Identify Intracellular Pathway of Alfacells Onconase
5. In vivo Study Results Demonstrating Potential of Alfacells Onconase for Treatment of Non-Small Cell Lung Cancer Published in Anticancer Research
6. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
7. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
10. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
11. NCCN Updates Esophageal and Gastric Cancer Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... SAN DIEGO , July 25, 2014  Arena ... it will provide a corporate update and report second ... Market opens on Friday, August 1, 2014. That same ... at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). ... by dialing 877.643.7155 for domestic callers and 914.495.8552 for ...
(Date:7/24/2014)... PARK, Kan. , July 24, 2014 /PRNewswire/ ... of two compounds that will be added to ... with Australian-based CIMTECH Pty Ltd, a biotechnology company. ... PAR 122 have shown promise in bone regeneration ... license to develop the compounds for the veterinary ...
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... , Weltweite Exklusivlizenz ... ermöglicht QIAGEN die Entwicklung von Tests auf ... Blutkrebs  Neuer Test weist Mutationen ... Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf vermuten ...
Breaking Medicine Technology:Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... Texas--(BUSINESS WIRE)--Apr 3, 2007 - Repros,Therapeutics Inc. (NasdaqGM:RPRX) ... of Proellex(TM), an oral drug being developed to,relieve ... with Proellex results in a statistically highly,significant improvement ... well tolerated., Study Details and Results , This ...
... 03, 2007,/PRNewswire-FirstCall/ -- Cell Genesys, Inc. today ... Phase 2 trial of GVAX,immunotherapy for prostate ... in 80 patients with metastatic,hormone-refractory prostate cancer ... received the dose that is comparable to ...
Cached Medicine Technology:Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 2Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 3Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 4Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 5Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer 2Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer 3
(Date:7/25/2014)... (PRWEB) July 25, 2014 Consuming too ... How to know? , Read the labels! , Learn ... determine how it relates to health during a "Healthy ... Aug. 1 at Humility House, 755 Ohltown Road, Austintown. ... lead an informational discussion and answer questions. , ...
(Date:7/25/2014)... City, UT (PRWEB) July 25, 2014 ... court surfaces for the recent Nike National Invitational ... the current United States Junior National Tournament (USJN) ... July 25. , The flooring for these prestigious national ... more than 300,000 square feet of playing surface at ...
(Date:7/25/2014)... 2014 As reported by People Magazine in ... Jersey Shore and Getting Sober (7/15), one of the ... has spoken out to the public about his personal transformation. ... The Situation admits that moving on with his life was ... and other drugs in 2012 and even spent some time ...
(Date:7/25/2014)... July 25, 2014 (HealthDay News) -- The human brain ... of dehydration, a new study finds. Although ... in England have found that the brain compensates by ... blood. "This research has helped us understand a ... extreme exercise in extreme conditions," study first author Steven ...
(Date:7/25/2014)... Art of Facial Surgery has recently stepped up ... who are looking for minor touch-ups to make them more ... American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) ... surgery showed a surprising increase between 2012 and 2013. ... transplants increased by 7 percent and eyelid surgery increased by ...
Breaking Medicine News(10 mins):Health News:Learn to Decipher Food Labels at Humility House 2Health News:Sport Court Provides All Sports Flooring for Basketball Events in Chicago and Washington D.C. 2Health News:'The Situation' Celebrates 8 Months of Sobriety 2Health News:'The Situation' Celebrates 8 Months of Sobriety 3Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:Art of Facial Surgery Responds to Demand for Facial Plastic Surgery Increase Due to the Popularity of Selfies 2Health News:Art of Facial Surgery Responds to Demand for Facial Plastic Surgery Increase Due to the Popularity of Selfies 3
... , , , ... Dr. Raymond Boyle, Ph.D., M.P.H., will be the new Director of ... and Epidemiology from the University of Oregon and the University of ... this new addition to ClearWay Minnesota and our research department," said ...
... explain why some function fine on six hours a night , ... by just fine on six hours of sleep, and a new ... finding doesn,t appear likely to help people with insomnia. Still, it ... long as they do, said study co-author Ying-Hui Fu, a professor ...
... Aug. 13 The following statement was released today by United ... comprehensive health care has been a high priority for the disability ... Act (H.R. 3200) will make significant strides toward meeting that goal. ... , Major insurance market reforms such as ...
... , BASKING RIDGE, N.J., Aug. 13 ... record-keeping, protecting confidential patient information becomes vastly more complex. ... designed to help safeguard the growing exchange of electronic patient ... , The first offering, Verizon Security Management ...
... , , , , ... busy preparing their children for departure for school, it is just ... from bringing bed bugs home from college and their travels. ... in the New York Metropolitan area, has seen a significant increase ...
... , MIAMI BEACH, Fla., Aug. 13 Centers ... facilities in Florida at the Florida Health Care Conference in Hollywood, ... for pressure ulcer management from the Florida Agency for Health Care ... Weaver, Chief of Field Operations, Division of Managed Care and Health ...
Cached Medicine News:Health News:They Snooze Less, But They Don't Lose 2Health News:Verizon Introduces New IT Security Capabilities for Health Care Industry 2Health News:Verizon Introduces New IT Security Capabilities for Health Care Industry 3Health News:Verizon Introduces New IT Security Capabilities for Health Care Industry 4Health News:Bed Bug Epidemic and Upcoming School Breaks Could Wreak Havoc on Homeowners 2Health News:Bed Bug Epidemic and Upcoming School Breaks Could Wreak Havoc on Homeowners 3Health News:Centers of Excellence Awards Presented to Over 100 Nursing Facilities as Nursing Facilities Reach the 'Tipping Point' in Treating Pressure Ulcers 2
... knee manufacturers focus attention on implant design, ... The Profix Total Knee System seeks to ... implant system and the tools to implant ... widely recognized for innovation in total knee ...
Cruciate retaining, posterior stabilized and constrained components....
Cruciate retaining, posterior stabilized and constrained components....
Maximum contact. Minimum wear. Outstanding results....
Medicine Products: